RT Journal Article
SR Electronic
T1 The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.24.20111914
DO 10.1101/2020.05.24.20111914
A1 Freeman, Esther E.
A1 McMahon, Devon E.
A1 Lipoff, Jules B.
A1 Rosenbach, Misha
A1 Kovarik, Carrie
A1 Desai, Seemal R.
A1 Harp, Joanna
A1 Takeshita, Junko
A1 French, Lars E.
A1 Lim, Henry W.
A1 Thiers, Bruce H.
A1 Hruza, George J.
A1 Fox, Lindy P.
YR 2020
UL http://medrxiv.org/content/early/2020/05/25/2020.05.24.20111914.abstract
AB Question What are the cutaneous manifestations associated with COVID-19 and do they provide insight into the pathophysiology or prognosis?Findings In this international registry-based case series of 716 patients representing 31 countries, the most common dermatologic morphologies encountered in the 171 COVID-19 confirmed case included morbilliform, pernio-like, urticarial, macular erythema, vesicular, papulosquamous, and retiform purpura. Retiform purpura was seen exclusively in critically ill, hospitalized patients.Meaning COVID-19 is associated with a spectrum of skin findings in affected patients. These cutaneous manifestations may vary depending on the severity of COVID-19.Competing Interest StatementDrs. Freeman, Lipoff, Rosenbach, Kovarik, Desai, Takeshita, Hruza Thiers and Fox are part of the American Academy of Dermatology (AAD) COVID-19 Ad Hoc Task Force. Dr. French is president and Dr. Lim is board member of the International League of Dermatological Societies (ILDS). Dr. Hruza is immediate past president of the AAD. Dr. Thiers is the President of the AAD.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The registry was approved by the Partners Healthcare (MGH) Institutional Review Board (IRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are housed through Partners healthcare Redcap and are not publicly available.